Please ensure Javascript is enabled for purposes of website accessibility

Guardant Health's Blood Cancer Test Detects Early-Stage Colon Cancer

By Brian Orelli, PhD – Jun 22, 2020 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Results from a small study will need to be validated by an ongoing study of 10,000 patients.

Results from a study by Guardant Health (GH 5.74%), presented at the American Association for Cancer Research Virtual Annual Meeting II, showed the company's Lunar-2 blood test can detect early-stage colon cancer.

Lunar-2 uses blood to detect cell-free DNA from tumor cells using three different types of changes seen in tumor DNA compared to normal DNA. After training the test on known samples, the study tested blood blinded samples from 113 patients who were known to have colon cancer and 88 patients who were deemed negative for colon cancer by colonoscopy.

In the study, Lunar-2 had a sensitivity of 90%, meaning it detected 90% of patients who actually had colon cancer. The test had a specificity of 96.6%, meaning it correctly identified 96.6% of patients who didn't have the cancer.

The results compare well to Exact Sciences' (EXAS 9.13%) stool-sample test Cologuard, which had a sensitivity of 92% to 94% depending on the stage of colon cancer and a specificity of 90% in patients with negative colonoscopy results.

Doctor talking to a patient in his office

Image source: Getty Images.

Shares of Guardant Health were up 5% at 3:22 p.m. EDT on the news, while Exact Sciences had slipped 2%.

Guardant Health is currently running a prospective clinical trial of 10,000 patients at average risk for colon cancer to validate the Lunar-2 test. The healthcare company was shooting for enrolling the study by November 2021, but COVID-19 has thrown a wrench in the enrollment process, with patients delaying non-emergency doctor visits.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Guardant Health. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health Stock Quote
Guardant Health
GH
$52.34 (5.74%) $2.84
Exact Sciences Stock Quote
Exact Sciences
EXAS
$44.95 (9.13%) $3.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.